Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020108915 - INFANT NUTRITIONAL COMPOSITION FOR USE IN THE ENHANCEMENT OF PANCREATIC MATURATION AND INSULIN BIOSYNTHESIS

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS :

1 . A nutritional composition comprising at least one fucosylated oligosaccharide for use in enhancing the pancreatic development and/or pancreatic maturation of infants or young children.

2. The nutritional composition of claim 1 wherein said at least one fucosylated oligosaccharide is present in a total amount of between 0.05-3 g/L of the composition, preferably at least 0.2g/L or at least 0.5g/L, and/or in a total amount of between 0.007-0.45 g/100g, preferably at least 0.03g/100g or at least 0.075g/1 OOg of composition on a dry weight basis.

3. The nutritional composition of any of the preceding claims wherein said fucosylated oligosaccharide is 2FL.

4. The nutritional composition of any of the preceding claims wherein said composition comprises a N-acetylated oligosaccharide.

5. The nutritional composition of any of the preceding claims wherein said N-acetylated oligosaccharide is lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT), para-lacto-N-neohexaose (para-LNnH), disialyllacto-N-tetraose (DSLNT) or any combination thereof.

6. The nutritional composition of any of the preceding claims wherein said N-acetylated oligosaccharide is present in a total amount of between 0.025-1 .5 g/L of the composition, preferably at least 0.1 g/L or at least 0.25g/L, and/or in a total amount of between 0.003-0.23 g/100g, preferably at least 0.015g/1 OOg or at least 0.03g/1 OOg of composition on a dry weight basis.

7. The nutritional composition of any of the preceding claims wherein said infants are between 0 and 12 months.

8. The nutritional composition of any of the preceding claims wherein said enhancement of pancreatic development or maturation further comprises or is mediated or is accompanied by the enhancement of the level of biosynthesis of insulin by the pancreatic cells of the infant or young child.

9. The nutritional composition of any of the preceding claims for further use in improving the glucose management of the infants during the administration period and/or during infancy and/or later in life, preferably reducing the risk of type-2 diabetes and/or obesity.

10. The nutritional composition of any of the preceding claims wherein said infants are subject in needs and/or are at risk of under-development of pancreas and/or are born preterm and/or suffering from intra-uterine-growth retardation (IUGR) and/or born with low birth weight (LBW), very- low-birth-weight (VLBW), or extremely-low-birth-weight (ELBW).

1 1 . The nutritional composition of any of the preceding claims wherein said nutritional composition is an Infant Formula, or a supplement for infants or young children, or a fortifier for Human Breast Milk, or a follow-on formula, or a Growing-Up Milk.

12. The nutritional composition of any of the preceding claims wherein said composition is to be administered during the first 1 , 2, 3, 6, or 12 months of life, and/or administered in an amount and/or a duration sufficient to induce a measurable enhancement of the pancreatic development or pancreatic maturation of said infants.

13. The nutritional composition of any of the preceding claims wherein said composition further comprises Sialyllactose, preferably 3SL or 6SL.

14. The nutritional composition of any one of the preceding claims, comprising at least another oligosaccharide(s) and/or fiber(s) and/or precursor(s) thereof selected from the list comprising galacto-oligosaccharides (GOS), fructo-

oligosaccharides (FOS), xylooligosaccharides (XOS), inulin, polydextrose, sialylated oligosaccharides, sialic acid, fucose and any combination thereof.

15. The nutritional composition of any one of the preceding claims, said composition further comprising at least one probiotic, live or in a non-replicating form, in an amount of from 103 to 1012 cfu/g of said composition (dry weight).

16. The nutritional composition of any one of the preceding claims wherein said composition is an infant formula, said N-acetylated oligosaccharide is LNnT and said fucosylated oligosaccharide is 2FL, and wherein said infant is a preterm infant, optionally said composition being fed during the first 6 months of life to said infant.